MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Avatud

SektorTervishoid

29.47 0.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.85

Max

29.82

Põhinäitajad
By Trading Economics
Sissetulek	7.7M -41M
Müük	3.5M 110M
Kasumimarginaal	-37.032
Töötajad	1,869
EBITDA	1.4M -55M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+68.33% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-700M 3.5B
Eelmine avamishind	29.23
Eelmine sulgemishind	29.47

Uudiste sentiment

By Acuity

100%

357 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

28.13 / 31.12 Toetus ja vastupanu

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. okt 2025, 22:33 UTC

Tulu

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14. okt 2025, 22:21 UTC

Suurimad hinnamuutused turgudel

Dentsply Sirona Shares Rise After SEC Probe Ends

14. okt 2025, 19:27 UTC

Omandamised, ülevõtmised, äriostud

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14. okt 2025, 17:56 UTC

Suurimad hinnamuutused turgudel

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14. okt 2025, 23:38 UTC

Market Talk

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14. okt 2025, 22:12 UTC

Market Talk

Tulu

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14. okt 2025, 21:40 UTC

Tulu

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14. okt 2025, 21:39 UTC

Tulu

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14. okt 2025, 21:38 UTC

Tulu

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14. okt 2025, 21:06 UTC

Tulu

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14. okt 2025, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

14. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. okt 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

14. okt 2025, 20:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

14. okt 2025, 20:13 UTC

Tulu

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14. okt 2025, 20:01 UTC

Tulu

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14. okt 2025, 19:21 UTC

Market Talk

Tulu

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14. okt 2025, 19:12 UTC

Omandamised, ülevõtmised, äriostud

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14. okt 2025, 19:08 UTC

Market Talk

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14. okt 2025, 18:59 UTC

Omandamised, ülevõtmised, äriostud

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14. okt 2025, 18:58 UTC

Omandamised, ülevõtmised, äriostud

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14. okt 2025, 18:58 UTC

Omandamised, ülevõtmised, äriostud

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14. okt 2025, 18:56 UTC

Omandamised, ülevõtmised, äriostud

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14. okt 2025, 18:46 UTC

Tulu

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14. okt 2025, 18:04 UTC

Tulu

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14. okt 2025, 18:01 UTC

Market Talk

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14. okt 2025, 17:54 UTC

Tulu

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14. okt 2025, 17:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. okt 2025, 17:50 UTC

Market Talk

Lower Dollar Provides Some Strength in Grains -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

68.33% tõus

12 kuu keskmine prognoos

Keskmine 52.57 USD 68.33%

Kõrge 69 USD

Madal 39 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.13 / 31.12Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.